Postdoctoral Researcher

TN Germany; Heidelberg; Vor Ort; EUR 45.000 - 65.000; Vollzeit

Zusammenfassung

Ein dynamisches internationales Team sucht einen engagierten Postdoktoranden, der sich der Krebsforschung widmet. In dieser Rolle werden Sie die molekularen Auswirkungen von IDH1-Mutationen untersuchen und modernste Technologien einsetzen, um epigenetische Veränderungen zu analysieren. Ihre Arbeit wird dazu beitragen, neue Behandlungsmöglichkeiten für Patienten mit IDH1-mutierten Malignitäten zu entwickeln. Diese Position bietet hervorragende Rahmenbedingungen, einschließlich modernster Ausrüstung, internationaler Vernetzungsmöglichkeiten und Unterstützung für Ihre persönliche Entwicklung. Wenn Sie leidenschaftlich an der Krebsforschung interessiert sind und bereit sind, einen bedeutenden Beitrag zu leisten, ist dies die perfekte Gelegenheit für Sie.

Leistungen

30 Tage Urlaub pro Jahr

Familienfreundliches Arbeitsumfeld

Subventioniertes Deutschland Jobticket

Zugang zum DKFZ International Postdoc Programm

Betriebliche Altersvorsorge

Gesundheitsmanagement-Programm

Qualifikationen

• Erfahrung in der molekularen und zellulären Biologie erforderlich.
• Veröffentlichungen in internationalen Fachzeitschriften sind notwendig.

Aufgaben

• Untersuchung molekularer Defekte durch onkogene IDH1-Mutationen.
• Verwendung modernster Technologien zur Analyse epigenetischer Veränderungen.

Kenntnisse

Molekulare Biologie

Zellbiologie

Epigenomik

Experimentelle Hämatologie

Kommunikationsfähigkeiten

Ausbildung

Ph.D. in Biologie

Ph.D. in Biochemie

Ph.D. in Biotechnologie

Tools

EpiCyTOF

RNA-seq

CRISPRi

CRISPRa

Nanopore Sequencing

Jobbeschreibung

Social network you want to login/join with:

• Translational Medical Oncology at DKFZ and NCT Heidelberg

“Research for a life without cancer" is our mission at the German Cancer Research Center. We investigate how cancer develops, identify cancer risk factors and look for new cancer prevention strategies. We develop new methods with which tumors can be diagnosed more precisely and cancer patients can be treated more successfully. Every contribution counts – whether in research, administration or infrastructure. This is what makes our daily work so meaningful and exciting.

The German Cancer Research Center (DKFZ) is seeking for the National Center for Tumor Diseases (NCT) Heidelberg for as soon as possible a

The Section of Translational Cancer Epigenomics headed by Dr. Daniel Lipka is part of the Division of Translational Medical Oncology at the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) Heidelberg. We are a dynamic international group of scientists working together with renowned national and international collaboration partners. In our group, we combine basic and translational research to discover and implement novel diagnostic and therapeutic approaches to malignant diseases. The main focus is on the analysis of epigenomic alterations occurring in premalignant and malignant cells as compared to their normal counterparts in order to understand how aberrant epigenetic programming impacts on tumor initiation and progression.

Your Tasks

The postdoctoral researcher will work as part of an interdisciplinary team of scientists investigating the molecular defects elicited by oncogenic IDH1 mutations. IDH1 mutations are found in several malignancies and result in the production of the oncometabolite D-2- hydroxyglutarate (D2HG). D2HG was shown to alter epigenetic regulation and to support tumorigenesis. However, the prescise molecular mechanisms underlying the tumorigenic effects of mutant IDH1 remain elusive. The successful candidate will use established in vitro and in vivo models of mutant IDH1 to assess the early and cell type-specific effects of mutant IDH1 on genetic and epigenetic integrity and the resulting transcriptional aberrations that provide a fertile soil for malignant transformation. These studies will involve the use of cutting-edge technologies (EpiCyTOF, metabolomics, ACT-, ATAC-, RNA-seq, nanopore sequencing, CRISPRi and CRISPRa) to assess the molecular aberrations involved and their consequences on cell function and phenotype. Ultimately, these results might lead to the development of novel treatment options beyond inhibition of the mutant enzyme for patients with IDH1-mutant malignancies.

Your Profile

We are looking for a highly motivated and ambitious postdoctoral scientist who is committed to cancer research at the crossroads of experimental hematology, epigenomics and metabolism. The candidate should be able to work independently but should also have excellent teamwork skills. Applicants must hold a Ph.D. in biology, biochemistry, biotechnology, or a related field, and have published previously in international peerreviewed journals. Expertise in molecular and cellular biology, with a specific focus on experimental hematology and/or epigenomics is advantageous. Profound knowledge of cancer biology, strong communication skills, and excellent written and oral command of English are required.

The application should include a curriculum vitae, a motivation letter, degree certificates, the expected availability date, a complete list of publications, and the names and contact information of at least two references.

We Offer

Excellent framework conditions: state-of-the-art equipment and opportunities for international networking at the highest level

Remuneration according to TV-L incl. occupational pension plan and capital-forming payments

30 days of vacation per year

Possibility of part-time work

Family-friendly working environment

Sustainable travel to work: subsidized Germany job ticket

Our Corporate Health Management Program offers a holistic approach to your well-being

Develop your full potential: access to the DKFZ International Postdoc Program and DKFZ Career Service with targeted offers for your personal development to further develop your talents